--- title: "Nitin Rohatgi, M.D., MBA | Sutter Health" url: "https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Investigators](https://www.sutterhealth.org/research/investigators) / 4. Nitin Rohatgi, M.D., MBA ![Nitin Rohatgi, M.D., MBA](https://dyn.mktgcdn.com/p/tVS4RemP6bkC55e_mitBU2bV-F97uZqUB_hdGp4TZ6s/fit=crop,gravity=auto,dpr=2,width=240,height=240) # Nitin Rohatgi, M.D., MBA Investigator [View profile](https://www.sutterhealth.org/find-provider/dr-nitin-rohatgi-1046241056) [View All Publications from PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=nitin+rohatgi) Nitin Rohatgi, MD, MBA is a board-certified medical oncologist specializing in breast and genitourinary (GU) cancers, with a strong focus on clinical research and innovation in digital health and artificial intelligence in medicine. He currently practices at Sutter Medical Group/Sutter Medical Center Sacramento, where he has served since 2008 and leads the Breast Cancer Program as Medical Director. Dr. Rohatgi brings extensive clinical and administrative leadership experience, including serving as Chair of the Section of Hematology/Oncology at Sutter Medical Center Sacramento for over 15 years and leading system-wide oncology initiatives within Sutter Health. His clinical interests center on advancing evidence-based treatments and improving outcomes in breast and GU oncology. He completed his hematology/oncology fellowship at the University of Cincinnati, where he also served as an Instructor of Clinical Medicine, following residency training in internal medicine at the University of Massachusetts. Dr. Rohatgi earned his MBBS from the All India Institute of Medical Sciences in New Delhi and an MBA with distinction from Heriot-Watt University. An active member of the American Society of Clinical Oncology, Dr. Rohatgi has authored numerous peer-reviewed publications and presented at national meetings, contributing to advancements in oncology therapeutics and translational research. ## Publications [View All Publications from PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=nitin+rohatgi) - Publication ### [Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.](https://www.sutterhealth.org/research/publications/phase-ii-trial-of-sequential-therapy-1055312593) Am J Hematol. 2002 Jul;70(3):181-5. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Rohatgi N1, LaRocca RV, Bard V, Sethuraman G, Foon KA. Am J Hematol. 2002 Jul;70(3):181-5. 2002 Jul 20 - Publication ### [Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.](https://www.sutterhealth.org/research/publications/raloxifene-is-associated-with-less-side-effects-th-1055312770) J Womens Health Gend Based Med. 2002 Apr;11(3):291-301. J Womens Health Gend Based Med. 2002 Apr;11(3):291-301. 2002 Apr 20 [View All Publications from PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=nitin+rohatgi) ## Clinical trials - Clinical trial ### [Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01](https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471) IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment **Status:** Closed to Enrollment - Clinical trial ### [Adjuvant Triple NegativeBreast Cancer Ascent-05](https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy **Status:** Open to Enrollment - Clinical trial ### [Advanced Melanoma Ignyte-3](https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355) Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Advance or Metastatic Breast Cancer Kandela-302](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-advance-or-metastatic-breast-cancer-kandela-302-2096506116) An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease **Status:** Coming Soon Page 1 of 2 ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Investigators","item":"https://www.sutterhealth.org/research/investigators"},{"@type":"ListItem","position":4,"name":"Nitin Rohatgi, M.D., MBA"}]} ``` ```json {"@context":"https://schema.org","@type":"ProfilePage","@id":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017#profilepage","url":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017","name":"Nitin Rohatgi, M.D., MBA","dateModified":"2026-06-05","breadcrumb":{"@id":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017#breadcrumblist"},"primaryImageOfPage":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/tVS4RemP6bkC55e_mitBU2bV-F97uZqUB_hdGp4TZ6s/480x480.jpg","width":480,"height":480},"mainEntity":{"@id":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017"}} ``` ```json {"@context":"https://schema.org","@type":"Person","@id":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017","name":"Nitin Rohatgi, M.D., MBA","givenName":"Nitin","familyName":"Rohatgi","honorificSuffix":"M.D., MBA","description":"Nitin Rohatgi, MD, MBA is a board-certified medical oncologist specializing in breast and genitourinary (GU) cancers, with a strong focus on clinical research and innovation in digital health and artificial intelligence in medicine. He currently practices at Sutter Medical Group/Sutter Medical Center Sacramento, where he has served since 2008 and leads the Breast Cancer Program as Medical Director. Dr. Rohatgi brings extensive clinical and administrative leadership experience, including serving as Chair of the Section of Hematology/Oncology at Sutter Medical Center Sacramento for over 15 years and leading system-wide oncology initiatives within Sutter Health. His clinical interests center on advancing evidence-based treatments and improving outcomes in breast and GU oncology. He completed his hematology/oncology fellowship at the University of Cincinnati, where he also served as an Instructor of Clinical Medicine, following residency training in internal medicine at the University of Massachusetts. Dr. Rohatgi earned his MBBS from the All India Institute of Medical Sciences in New Delhi and an MBA with distinction from Heriot-Watt University. An active member of the American Society of Clinical Oncology, Dr. Rohatgi has authored numerous peer-reviewed publications and presented at national meetings, contributing to advancements in oncology therapeutics and translational research.","image":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/tVS4RemP6bkC55e_mitBU2bV-F97uZqUB_hdGp4TZ6s/480x480.jpg","representativeOfPage":true},"affiliation":{"@id":"https://www.sutterhealth.org/#medicalorganization"},"mainEntityOfPage":{"@id":"https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017#profilepage"},"sameAs":"https://www.sutterhealth.org/find-provider/dr-nitin-rohatgi-1046241056"} ```